Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?

BACKGROUND: In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these early efficacy metrics are still predictive of long...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Meihua, Chen, Cong, Jemielita, Thomas, Anderson, James, Li, Xiaoyun (Nicole), Hu, Chen, Kang, S. Peter, Ibrahim, Nageatte, Ebbinghaus, Scot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368769/
https://www.ncbi.nlm.nih.gov/pubmed/30736858
http://dx.doi.org/10.1186/s40425-019-0513-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368769/
https://www.ncbi.nlm.nih.gov/pubmed/30736858
http://dx.doi.org/10.1186/s40425-019-0513-4

Ejemplares similares